Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection

Abstract

The recent discovery of small molecules targeting the cytochrome bc 1 :aa 3 in Mycobacterium tuberculosis triggered interest in the terminal respiratory oxidases for antituberculosis drug development. The mycobacterial cytochrome bc 1 :aa 3 consists of a menaquinone:cytochrome c reductase (bc 1 ) and a cytochrome aa 3 -type oxidase. The clinical-stage drug candidate Q203 interferes with the function of the subunit b of the menaquinone:cytochrome c reductase. Despite the affinity of Q203 for the bc 1 :aa 3 complex, the drug is only bacteriostatic and does not kill drug-tolerant persisters. This raises the possibility that the alternate terminal bd-type oxidase (cytochrome bd oxidase) is capable of maintaining a membrane potential and menaquinol oxidation in the presence of Q203. Here, we show that the electron flow through the cytochrome bd oxidase is sufficient to maintain respiration and ATP synthesis at a level high enough to protect M. tuberculosis from Q203-induced bacterial death. Upon genetic deletion of the cytochrome bd oxidase-encoding genes cydAB, Q203 inhibited mycobacterial respiration completely, became bactericidal, killed drugtolerant mycobacterial persisters, and rapidly cleared M. tuberculosis infection in vivo. These results indicate a synthetic lethal interaction between the two terminal respiratory oxidases that can be exploited for anti-TB drug development. Our findings should be considered in the clinical development of drugs targeting the cytochrome bc 1 :aa 3 , as well as for the development of a drug combination targeting oxidative phosphorylation in M. tuberculosis.bioenergetics | oxidative phosphorylation | persisters | Q203 | bedaquiline

Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease

“…The electron‐transport chain is imperative in the maintenance of electrochemical gradients within cells. It drives the biosynthesis of ATP and is required for survival of both replicating and nonreplicating mycobacteria . Accordingly, cellular respiration has become an attractive target for antimycobacterial drug discovery and antimicrobial drug discovery in general .…”

Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay

“…The ATP synthase inhibitor bedaquiline (BDQ) has significant treatment-shortening effects in mouse TB models and is a core component of novel treatment-shortening regimens for both drug-susceptible and multidrug-resistant TB (10)(11)(12)(13)(14)(15)(16). The cytochrome bc 1 :aa 3 complex inhibitor Q203 has efficacy in mouse TB models and is poised to enter phase 2 trials in TB patients (17,18). Clofazimine is reduced by NDH-2 (type II dehydrogenase), which is the point of entry of electrons into the respiratory chain (9,19).…”

Comparative Genomics Shows Differences in the Electron Transport and Carbon Metabolic Pathways ofMycobacterium africanumrelative toMycobacterium tuberculosisand suggests an adaptation to low oxygen tension

“…cydAB encodes cytochrome-bd menaquinol oxidase, which functions under microaerophilic conditions and supports aerobic growth during inhibition of the cytochrome bc1 complex (34, 104, 105), also mutated in MAF based on our findings. Notably, the respiratory inhibitor, Q203, which targets the primary terminal oxidase, cytochrome bc1-aa3, is bacteriostatic in M. tuberculosis because M. tuberculosis has the alternate cytochrome bd-type terminal oxidase that, to an extent, serves as a rescue when the bc1-aa3 complex is defective.…”